Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) SVP Bruce Leicher sold 859 shares of the firm’s stock in a transaction dated Monday, May 22nd. The stock was sold at an average price of $14.80, for a total value of $12,713.20. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Bruce Leicher also recently made the following trade(s):

  • On Wednesday, May 10th, Bruce Leicher sold 347 shares of Momenta Pharmaceuticals stock. The stock was sold at an average price of $16.00, for a total value of $5,552.00.

Shares of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) traded down 0.68% during midday trading on Tuesday, reaching $14.70. The company’s stock had a trading volume of 1,026,918 shares. Momenta Pharmaceuticals, Inc. has a 52-week low of $9.66 and a 52-week high of $19.90. The stock has a 50-day moving average price of $14.45 and a 200-day moving average price of $14.90. The stock’s market cap is $1.04 billion.

Momenta Pharmaceuticals (NASDAQ:MNTA) last announced its earnings results on Tuesday, May 2nd. The biotechnology company reported ($0.46) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.09) by $0.63. Momenta Pharmaceuticals had a negative return on equity of 26.55% and a negative net margin of 93.75%. The firm had revenue of $26.61 million during the quarter, compared to analyst estimates of $21.29 million. During the same quarter in the prior year, the company earned ($0.35) EPS. The business’s revenue was up 34.1% compared to the same quarter last year. Equities research analysts anticipate that Momenta Pharmaceuticals, Inc. will post ($1.43) earnings per share for the current fiscal year.

Insider Buying and Selling by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)

ILLEGAL ACTIVITY WARNING: “Momenta Pharmaceuticals, Inc. (MNTA) SVP Bruce Leicher Sells 859 Shares” was originally posted by American Banking News and is the property of of American Banking News. If you are reading this article on another publication, it was illegally copied and republished in violation of United States & international trademark and copyright law. The legal version of this article can be read at https://www.americanbankingnews.com/2017/05/23/momenta-pharmaceuticals-inc-mnta-svp-bruce-leicher-sells-859-shares.html.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Patten Group Inc. purchased a new position in shares of Momenta Pharmaceuticals during the third quarter valued at about $148,000. Dynamic Technology Lab Private Ltd purchased a new position in shares of Momenta Pharmaceuticals during the first quarter valued at about $158,000. Municipal Employees Retirement System of Michigan raised its position in shares of Momenta Pharmaceuticals by 2.0% in the third quarter. Municipal Employees Retirement System of Michigan now owns 14,170 shares of the biotechnology company’s stock valued at $166,000 after buying an additional 280 shares in the last quarter. Pacad Investment Ltd. raised its position in shares of Momenta Pharmaceuticals by 68.7% in the fourth quarter. Pacad Investment Ltd. now owns 11,300 shares of the biotechnology company’s stock valued at $170,000 after buying an additional 4,600 shares in the last quarter. Finally, BNP Paribas Arbitrage SA raised its position in shares of Momenta Pharmaceuticals by 13.3% in the first quarter. BNP Paribas Arbitrage SA now owns 13,393 shares of the biotechnology company’s stock valued at $179,000 after buying an additional 1,570 shares in the last quarter. 84.44% of the stock is owned by hedge funds and other institutional investors.

MNTA has been the subject of a number of research analyst reports. Leerink Swann set a $20.00 target price on Momenta Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, January 31st. Stifel Nicolaus lowered their target price on Momenta Pharmaceuticals from $30.00 to $26.00 and set a “buy” rating for the company in a report on Wednesday, May 3rd. Zacks Investment Research upgraded Momenta Pharmaceuticals from a “hold” rating to a “buy” rating and set a $16.00 target price for the company in a report on Wednesday, March 8th. TheStreet upgraded Momenta Pharmaceuticals from a “d” rating to a “c” rating in a report on Tuesday, February 21st. Finally, Barclays PLC downgraded Momenta Pharmaceuticals from an “overweight” rating to an “equal weight” rating and lowered their target price for the stock from $20.00 to $17.00 in a report on Monday. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and four have assigned a buy rating to the company. Momenta Pharmaceuticals has an average rating of “Hold” and a consensus target price of $16.60.

About Momenta Pharmaceuticals

Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).

12 Month Chart for NASDAQ:MNTA

Receive News & Ratings for Momenta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.